Cabot (CBT) Valuation After EPS Beat And Lower 2026 Outlook For Reinforcement Materials

Cabot (CBT) is back in focus after first quarter fiscal 2026 results that beat earnings estimates, but came with lower year over year sales and a trimmed adjusted EPS outlook.

See our latest analysis for Cabot.

The earnings beat has not stopped selling pressure in the short term, with a 1 day share price return of 5.40% decline and a 7 day share price return of 8.04% decline. At the same time, the 90 day share price return of 8.49% and 5 year total shareholder return of 46.88% point to a longer track record that investors are weighing against the trimmed outlook and ongoing softness in Reinforcement Materials.

If Cabot’s move has you reassessing materials names, it could be a good moment to look at how the market is pricing 20 top founder-led companies as potential long term compounders.

With earnings guidance trimmed and the share price pulling back despite a recent beat, the key question now is simple: is Cabot’s current valuation a discount on future growth, or has the market already priced it in?

Preferred P/E of 11.9x: Is it justified?

Cabot closed at $70.02, and on a P/E of 11.9x it screens cheaper than both its Chemicals peers and the wider US market on earnings.

P/E compares the share price to earnings per share, so a lower multiple can indicate the market is assigning a lower price tag to each dollar of profit. For a specialty chemicals and performance materials company like Cabot, investors often look at P/E alongside growth, returns and balance sheet risk to judge whether that earnings stream looks resilient.

Here, Cabot is described as good value on a P/E basis versus its peer average of 19.4x and the broader US Chemicals industry average of 24.3x. That gap is significant, and it sits alongside high quality earnings, a high 20.5% return on equity, and a track record of becoming profitable over the past five years, but also recent negatives such as a 26.6% earnings contraction, lower net profit margins year over year and a high level of debt funded from higher risk sources.

Compared to the sector, the discount is clear. Cabot’s 11.9x P/E sits well below the 19.4x peer average and the 24.3x US Chemicals industry average, which suggests the market is pricing its earnings more cautiously than many rivals despite its strong return on equity and history of earnings growth over five years.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-earnings of 11.9x (UNDERVALUED)

However, trimmed EPS guidance and pressure in Reinforcement Materials, alongside a 15.46% 1 year total return decline, could still weigh on how confidently the market values Cabot.

Find out about the key risks to this Cabot narrative.

Another View: DCF suggests a deeper discount

While the 11.9x P/E makes Cabot look cheap against Chemicals peers, our DCF model goes further, with an estimated future cash flow value of $94.96 versus a $70.02 share price. That 26.3% gap suggests the market may be pricing in a lot of caution, so what might shift sentiment from here?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cabot for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on value and outlook so far. If you want to move quickly and form your own view, take a look at 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you are weighing what to do next after Cabot, do not stop at one name. Broaden your watchlist now so you are not late to the next opportunity.

• Target potential mispricings by scanning our list of 49 high quality undervalued stocks that combine appealing prices with solid underlying businesses.
• Lock in income ideas by reviewing 16 dividend fortresses that focus on higher yielding companies with resilient payout profiles.
• Prioritise resilience by checking 63 resilient stocks with low risk scores that highlight companies with lower overall risk scores for steadier compounding.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com